Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMGN NASDAQ:RPRX NASDAQ:VRTX NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30$345.10$267.83▼$391.29$183.11B0.442.82 million shs1.57 million shsRPRXRoyalty Pharma$54.50$49.03$32.15▼$54.64$31.38B0.43.69 million shs3.05 million shsVRTXVertex Pharmaceuticals$434.52$441.55$362.50▼$507.92$110.28B0.31.23 million shs1.75 million shsZBIOZenas BioPharma$18.97$20.51$8.91▼$44.60$1.20B-0.61555,534 shs342,230 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen0.00%+3.98%-1.52%-10.57%+24.90%RPRXRoyalty Pharma0.00%+3.12%+10.37%+19.86%+67.95%VRTXVertex Pharmaceuticals0.00%-0.56%+0.95%-9.67%-0.34%ZBIOZenas BioPharma0.00%+3.44%+4.29%-27.43%+65.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMGNAmgen$339.30$345.10$267.83▼$391.29$183.11B0.442.82 million shs1.57 million shsRPRXRoyalty Pharma$54.50$49.03$32.15▼$54.64$31.38B0.43.69 million shs3.05 million shsVRTXVertex Pharmaceuticals$434.52$441.55$362.50▼$507.92$110.28B0.31.23 million shs1.75 million shsZBIOZenas BioPharma$18.97$20.51$8.91▼$44.60$1.20B-0.61555,534 shs342,230 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMGNAmgen0.00%+3.98%-1.52%-10.57%+24.90%RPRXRoyalty Pharma0.00%+3.12%+10.37%+19.86%+67.95%VRTXVertex Pharmaceuticals0.00%-0.56%+0.95%-9.67%-0.34%ZBIOZenas BioPharma0.00%+3.44%+4.29%-27.43%+65.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMGNAmgen 2.48Hold$355.194.68% UpsideRPRXRoyalty Pharma 3.00Buy$53.71-1.44% DownsideVRTXVertex Pharmaceuticals 2.92Moderate Buy$555.1727.77% UpsideZBIOZenas BioPharma 2.56Moderate Buy$44.29133.45% UpsideCurrent Analyst Ratings BreakdownLatest AMGN, ZBIO, VRTX, and RPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026AMGNAmgen ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$400.00 ➝ $375.005/18/2026VRTXVertex Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)5/15/2026RPRXRoyalty Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/15/2026ZBIOZenas BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026ZBIOZenas BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.005/14/2026ZBIOZenas BioPharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$21.00 ➝ $22.005/14/2026AMGNAmgen Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$432.00 ➝ $427.005/14/2026ZBIOZenas BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/13/2026AMGNAmgen Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$410.00 ➝ $390.005/7/2026AMGNAmgen Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/7/2026RPRXRoyalty Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $66.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMGNAmgen$36.75B4.98$33.79 per share10.04$17.03 per share19.92RPRXRoyalty Pharma$2.38B13.20$4.78 per share11.41$17.26 per share3.16VRTXVertex Pharmaceuticals$12.00B9.19$17.58 per share24.72$76.29 per share5.70ZBIOZenas BioPharma$10M119.76N/AN/A$5.32 per share3.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMGNAmgen$7.71B$14.3723.6114.403.4120.96%137.41%13.28%8/4/2026 (Estimated)RPRXRoyalty Pharma$770.95M$1.4737.089.891.5033.88%29.25%14.71%8/5/2026 (Estimated)VRTXVertex Pharmaceuticals$3.95B$16.8625.7722.851.8635.51%23.86%17.13%8/3/2026 (Estimated)ZBIOZenas BioPharma-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)Latest AMGN, ZBIO, VRTX, and RPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ZBIOZenas BioPharma-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A5/6/2026Q1 2026RPRXRoyalty Pharma$1.22$1.30+$0.08$0.67$881.69 million$631.00 million5/4/2026Q1 2026VRTXVertex Pharmaceuticals$4.24$4.47+$0.23$4.02$2.99 billion$2.99 billion4/30/2026Q1 2026AMGNAmgen$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion4/13/2026Q4 2025ZBIOZenas BioPharmaN/A-$1.10N/A-$0.98$40.00 millionN/A3/16/2026Q4 2025ZBIOZenas BioPharma-$1.22-$4.54-$3.32-$4.54$28.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMGNAmgen$10.082.97%+8.27%70.15%14 YearsRPRXRoyalty Pharma$0.941.72%+24.01%63.95%5 YearsVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ALatest AMGN, ZBIO, VRTX, and RPRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/17/2026RPRXRoyalty Pharmaquarterly$0.23501.78%5/15/20265/15/20266/10/20263/4/2026AMGNAmgenquarterly$2.523.09%5/15/20265/15/20266/5/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMGNAmgen5.651.261.01RPRXRoyalty Pharma0.862.662.66VRTXVertex PharmaceuticalsN/A3.022.57ZBIOZenas BioPharma1.0411.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMGNAmgen76.50%RPRXRoyalty Pharma54.35%VRTXVertex Pharmaceuticals90.96%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipAMGNAmgen0.85%RPRXRoyalty Pharma18.84%VRTXVertex Pharmaceuticals0.20%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMGNAmgen31,500539.68 million535.10 millionOptionableRPRXRoyalty Pharma80575.83 million467.35 millionOptionableVRTXVertex Pharmaceuticals6,400253.80 million253.30 millionOptionableZBIOZenas BioPharmaN/A63.13 million49.24 millionN/AAMGN, ZBIO, VRTX, and RPRX HeadlinesRecent News About These CompaniesZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 ...May 19, 2026 | markets.businessinsider.comHC Wainwright Predicts Lower Earnings for Zenas BioPharmaMay 19, 2026 | marketbeat.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressMay 19, 2026 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 60,000 SharesMay 19, 2026 | americanbankingnews.comZenas BioPharma (NASDAQ:ZBIO) CEO Purchases $1,012,800.00 in StockMay 19, 2026 | insidertrades.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comZenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS SegmentMay 18, 2026 | tipranks.comHead to Head Review: Zenas BioPharma (NASDAQ:ZBIO) vs. Elicio Therapeutics (NASDAQ:ELTX)May 18, 2026 | americanbankingnews.comVanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIOMay 16, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Raised to Sell at Wall Street ZenMay 16, 2026 | americanbankingnews.comZenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Hold" from AnalystsMay 15, 2026 | americanbankingnews.comWhy Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net LossMay 14, 2026 | uk.finance.yahoo.comZenas BioPharma Stock Short Interest Report | NASDAQ:ZBIO | BenzingaMay 13, 2026 | benzinga.comZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF InhibitorMay 13, 2026 | globenewswire.comZenas BioPharma Highlights Strong Q1 Progress and FinancingMay 13, 2026 | tipranks.comZenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory SubmissionsMay 13, 2026 | quiverquant.comQZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comZenas BioPharma (ZBIO) to Release Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.7% - Still a Buy?May 4, 2026 | marketbeat.comZenas BioPharma rises as CEO continues insider purchasesApril 30, 2026 | msn.comZenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026April 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMGN, ZBIO, VRTX, and RPRX Company DescriptionsAmgen NASDAQ:AMGN$339.30 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$340.28 +0.98 (+0.29%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Royalty Pharma NASDAQ:RPRX$54.50 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$54.46 -0.05 (-0.08%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Vertex Pharmaceuticals NASDAQ:VRTX$434.52 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$433.41 -1.11 (-0.26%) As of 05/22/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.Zenas BioPharma NASDAQ:ZBIO$18.97 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$19.05 +0.08 (+0.42%) As of 05/22/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
